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tigecycline or doxycycline against Klebsiella pneumoniae carbapenemase (KPC)-producing K.
pneumoniae isolates are rarely published. The goal of this study was to evaluate the antibac-
terial activity of the combination regimens.
Methods: Thirteen genetically different KPC-producing K. pneumoniae isolates were randomly
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were tested by combination studies.
Results: Treatment with the 1 MIC concentration in combinations of amikacin or gentamicin
and tigecycline or doxycycline for 24 hours resulted in bactericidal activity of 84e100% in the
isolates. Treatment with 1/2 MIC combinations resulted in synergism of 69e100% in the iso-
lates. Notably, doxycycline plus gentamicin or amikacin was synergistic for all tested isolates.
However, bactericidal or synergistic effect was barely evident following 1/4 MIC combina-
tions. There was no antagonism in any of the combination regimens.
Conclusion: Enhanced activity was noted following treatment with doxycycline combined with
gentamicin or amikacin against KPC-producing K. pneumoniae isolates, warranting further
in vitro and animal investigations before clinical application.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Global spread of carbapenem-resistant Enterobacteriaceae
(CRE) is a major health problem and a clinical challenge for
physicians.1,2 Additional carbapenemases, including Kleb-
siella pneumoniae carbapenemases (KPCs), emerged in
Gram-negative bacteria due to extensive use of carbape-
nems.3 A national surveillance of CRE in Taiwan in 2011
found a clonal dissemination of KPC-2-producing isolates
during the time period, and the prevalence rate of KPC-
producing K. pneumoniae was 22.3% in Taiwan in 2012.4e6
The optimal treatment for infections due to
carbapenemase-producing organisms is uncertain.7 Selec-
tion of antibiotic therapy should be tailored to antimicro-
bial susceptibility results for agents outside the beta-
lactam and carbapenem classes, such as colistin, tigecy-
cline, or fosfomycin.8e10 A recent study of the therapeutic
efficacy of various regimens for bloodstream infections
caused by KPC-producing K. pneumoniae emphasized the
importance of combination therapy.11 Doxycycline was
found to be active in vitro against some KPC isolates, which
was considered as a component of combination therapy.12
Additionally, doxycycline is almost completely absorbed,
with a bioavailability of > 80% (average, 95%), an average
area under the curve for daily 200 mg intravenous (IV) doses
from 61 mg$h/L to 112 mg$h/L, and a Cmax of 200 mg from
4.8 mg/L to 6.5 mg/L. Doxycycline also exhibited excellent
hepatic/biliary penetration and acceptable concentrations
in epithelial-lining fluid.13 Moreover, Elemam et al14
demonstrated that rifampin, doxycycline, or tigecycline in
combination with polymyxin B exhibited synergistic in vitro
activity against KPC-producing K. pneumoniae isolates.
Amikacin was also shown to be effective for treatment
against Gram-negative bacteria isolated from respiratory
tracts, with peak serum concentration ranges of
w17e26 mg/mL after a 7.5-mg/kg IV drip admin-
istration.15e17 Furthermore, amikacin plus doripenem was
reported to be an effective combination therapy in both
in vitro and in vivo infection models involving KPC-
producing K. pneumoniae isolates.18
Tigecycline plus gentamicin or colistin was effective in
treating KPC-producing K. pneumoniae infections in trauma
intensive care unit patients without other comorbidities.19ng H-J, et al., Colistin-sparing reg
f tigecycline or doxycycline and g
0.1016/j.jmii.2016.03.003Additionally, 15 articles involving 55 unique cases were
reviewed, showing that tigecycline and aminoglycosides
were associated with favorable outcomes in the majority of
KPC-producing K. pneumoniae infections.20 However,
in vitro studies of the combination effect of an amino-
glycoside and tigecycline or doxycycline have been rarely
reported. The goal of the study was to evaluate the in vitro
antibacterial activity of the combinations of an amino-
glycoside (gentamicin or amikacin) and tigecycline or
doxycycline against KPC-producing K. pneumoniae isolates.
Methods
Bacterial strains
Thirty-six clinical carbapenem-resistant K. pneumoniae
isolates were collected between January 2010 and
December 2012 from 17 hospitals in a multicenter surveil-
lance in Taiwan. The isolates were stored at 80C in
Protect Bacterial Preservers (Technical Service Consultants
Limited, Heywood, UK) before use. Carbapenem resistance
is defined as a MIC of at least 4 mg/mL for imipenem or
meropenem. Species confirmation was performed by stan-
dard biochemical methods using a VITEK 2 automated sys-
tem (bioMe´rieux, Marcy l’Etoile, France). The carriage of
KPC was confirmed by polymerase chain reaction.21
In vitro susceptibility
Standard powders of amikacin, ciprofloxacin, doxycycline,
ertapenem, gentamicin, levofloxacin, and imipenem were
obtained from U.S. Pharmacopeia (Rockville, MD, USA), and
meropenem was obtained from Sigma-Aldrich (St. Louis,
MO, USA). Doripenem was kindly provided by Shionogi
(Osaka, Japan), fosfomycin by Ercros (Barcelona, Spain),
and tigecycline by Pfizer (New York, NY, USA). MIC de-
terminations and susceptibility interpretation criteria fol-
lowed the Clinical Laboratory and Standard Institute (CLSI)
and Federal Drug Administration (FDA) standards.22,23 MICs
of the drugs, except tigecycline, were measured by agar
dilution in MuellereHinton agar (Oxoid, Basingstoke, UK),
according to CLSI recommendations. For fosfomycinimens against Klebsiella pneumoniae carbapenemase-producing K.
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to the agar plate. Tigecycline MICs were determined by
broth microdilution in freshly prepared MuellereHinton
broth with 25 mg/mL of calcium and 12.5 mg/mL of mag-
nesium (CAMHB) as recommended by CLSI guidelines.22,24
Escherichia coli ATCC 25922 was included as the control
strain in each run of MIC measurements.
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) was performed for
the KPC K. pneumoniae isolates. Briefly, bacterial chro-
mosomal DNAs were digested using XbaI (New England
Biolabs, Beverly, MA, USA). Electrophoresis was carried out
for 22 hours at 14 uC, with pulse times ranging from 2
seconds to 40 seconds at 6 V/cm, using a Bio-Rad CHEF
MAPPER apparatus (Bio-Rad Laboratories, Richmond, CA,
USA). A dendrogram based on the unweighted pair group
was generated using methods previously described.25 Iso-
lates that had > 80% similarity on the PFGE profiles were
considered closely related strains.
Time-killing method
Thirteen KPC-producing isolates were randomly selected
for the following study. The in vitro determination of
inhibitory effects of combination regimens followed the
methodology defined by the CLSI.26 Briefly, bacterial sus-
pensions were diluted to concentrations of 5.0105 colony-
forming units (CFU)/mL in fresh MuellereHinton broth.
Drug concentrations of amikacin, gentamicin, tigecycline,
and doxycycline were adjusted to those of 1 MIC, 1/2
MIC, and 1/4 MIC. Each drug alone or the combinations of
amikacin or gentamicin and tigecycline or doxycycline were
tested. Bacterial counts were measured at 24 hours by
enumerating the colonies in 10-fold serially diluted speci-
mens of 100 mL aliquots plated on nutrient agar (Difco
Laboratories, Sparks, MD, USA) at 37C.
Definitions
Synergism or antagonism was defined as a minimum 100-
fold reduction or increase of bacterial loads between the
combination and the most active constituent after 24
hours. Bacteriostatic activities were defined as the pres-
ence of  2 log10, but < 3 log10 reductions, and bactericidal
activities as the presence of  3 log10 reductions in CFU/mL
at 24 hours, relative to the initial inoculum.26 All experi-
ments were performed in duplicate.
Checkerboard method
To evaluate the effect of the combinations, the fractional
inhibitory concentration (FIC) was calculated for
each combination by the broth-microdilution technique
as recommended by the CLSI and as previously
described.22,27,28 The following formulas were used to
calculate the FIC index: (1) FIC of drug A Z MIC of drug A
in combination/MIC of drug A alone, (2) FIC of drug
BZ MIC of drug B in combination/MIC of drug B alone, and
(3) FIC indexZ FIC of drug A þ FIC of drug B. Synergy wasPlease cite this article in press as: Tang H-J, et al., Colistin-sparing reg
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Infection (2016), http://dx.doi.org/10.1016/j.jmii.2016.03.003defined as a FIC index of  0.5, indifference was defined
as a FIC index of > 0.5, but  4, and antagonism defined as
a FIC index of > 4.29
Results
Among 36 KPC-producing K. pneumoniae isolates, all con-
tained KPC-2, with the 50% and 90% MIC (MIC50/90) values of
the 11 drugs shown in Table 1. Amikacin was the most
active, with a susceptible rate of 94.4%, followed by
tigecycline (86.1%), gentamicin (79%), and doxycycline
(66.7%). According to the PFGE profile, 36 KPC-producing
K. pneumoniae isolates can be differentiated into five
types, from A to E (Figure 1). For in vitro combination
experiments, one to three isolates were randomly selected
from the five types, with a total of 13 clinical isolates
collected from blood, urine, wound, or sputum. The MICs
of amikacin, gentamicin, doxycycline, and tigecycline for
these 13 KPC-producing K. pneumoniae isolates are listed
in Table 2.
Combination studies
The in vitro activities of amikacin, gentamicin, tigecycline,
or doxycycline at drug concentrations of 1 MIC, 1/2 MIC,
and 1/4 MIC alone or in combinations are shown in Tables
3 and 4. For two doxycycline-resistant isolates, numbers 29
and 35 (MIC, > 128 mg/mL and 128 mg/mL, respectively),
time-kill studies of doxycycline-containing combinations
were not tested.
When KPC-producing K. pneumoniae isolates at an
inoculum of 5  105 CFU/mL were incubated with amikacin
at the concentration of 1 MIC plus 1 MIC doxycycline or
tigecycline as compared with the initial inoculum, the
reduction in CFU at 24 hours ranged from 1.17 log10 to
4.2 log10 and from 2.5 log10 to 4.26 log10, respectively,
and such combinations exhibited bactericidal effect
against 82% (9/11) and 85% (11/13) of the tested isolates,
respectively. When the drug concentrations decreased to
1/2 MIC, bacterial load reductions at 24 hours ranged
from 1.94 log10 to 4.2 log10 (amikacin plus doxycycline)
and 0.39 log10 to 4.08 log10 (amikacin plus tigecycline),
and 64% (7/11) and 31% (4/13) of the isolates exhibit
bactericidal effect, respectively. Notably, at concentra-
tions of 1/2 MIC amikacin plus 1/2 MIC doxycycline or
tigecycline, these two combinations were synergistic
against 100% (11/11) and 85% (11/13) of the isolates,
respectively.
In the case of gentamicin at a concentration of 1 MIC
plus 1 MIC doxycycline or tigecycline, the reduction in
CFU at 24 hours ranged from 2.46 log10 to 4.2 log10 or from
3.72 log10 to 4.38 log10, and bactericidal activity was
exhibited against 91% (10/11) and 100% (13/13) of the iso-
lates, respectively. At drug concentrations of 1/2 MIC in
combination, gentamicin plus doxycycline or tigecycline
exhibited bactericidal and synergistic activity against 73%
or 38% and 100% or 68% of the isolates, respectively.
With different drug combinations at variable concen-
trations, bacteriostatic or bactericidal activity and synergy
or antagonism are shown in Table 5. The combinations of 1/
2 MIC gentamicin or amikacin plus tigecycline wereimens against Klebsiella pneumoniae carbapenemase-producing K.
entamicin or amikacin, Journal of Microbiology, Immunology and
Table 1 MICs and interpretative breakpoints of 11 drugs for 36 Klebsiella pneumoniae carbapenemase-producing K. pneu-
moniae isolates.
Drugs MIC (mg/mL) Susceptible (%) MIC (mg/mL)
50% 90% Range S I R
Amikacin 2 8 1e>128 94.4 16 32 64
Gentamicin <0.5 16 <0.5e>128 79.0 4 8 16
Doxycycline 4 32 4e64 66.7 4 8 16
Tigecycline 2 4 1e4 86.1 2 4 8
Fosfomycin 64 >1024 32e>1024 50.0 64 128 256
Ciprofloxacin 128 >128 64e>128 0 1 2 4
Levofloxacin 128 256 32e256 0 2 4 8
Doripenem >32 >32 4e>32 0 1 2 4
Ertapenem >32 >32 4e>32 0 0.5 1 2
Imipenem 32 >64 16e>64 0 1 2 4
Meropenem >64 >64 16e>64 0 1 2 4
I Z intermediate; R Z resistant; S Z susceptible.
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2 MIC gentamicin or amikacin plus doxycycline was syn-
ergistic for all isolates. At drug concentrations of 1/4 MIC,
all four combinations exhibited poor antibacterial activity.
The data associated with the checkerboard method are
shown in Table 6. The 50% and 90% FICs (FIC50/FIC90) of
tigecycline- and doxycycline-based combinations was
w0.56e1.0 and w0.5e0.75. The combination effects of
amikin/tigecycline and gentamicin/tigecycline in the cat-
egories of synergy and indifference was 36.4% versus 63.6%
and 28.6% versus 71.4% of the isolates, respectively. How-
ever, the combination effects of amikin/doxycycline and
gentamicin/doxycycline in the categories of synergy and
indifference was 48.5% versus 51.5% and 67.6% versus 32.4%
of the isolates, respectively. The FIC index of the combi-
nation of gentamicin and doxycycline was the lowest in the
category of synergy and indifference for 67.6% and 32.4% of
the isolates, respectively, which have the highest per-
centage of synergy and constituted the most effective
regimen. There was no antagonistic effects observed
among the four combinations. The results of the checker-
board method were compatible with those of the 24-hour
time-killing method.Discussion
Carbapenemase-producing K. pneumoniae infections that
originate from contaminated endoscopic equipment have
been reported and successfully treated using tigecycline
plus amikacin.30 Compared with treatments involving tige-
cycline or colistin combined with a carbapenem or an
aminoglycoside, a worse outcome was noted in patients
receiving tigecycline or colistin monotherapy for the
treatment of KPC-producing K. pneumoniae bacteremia.31
Therefore, it is reasonable to recommend a combination
of tigecycline or colistin combined with an aminoglycoside
for serious infections due to KPC producers in Taiwan, as
both drugs were active against local KPC producers. Addi-
tionally, according to a therapeutic algorithm, an amino-
glycoside in combination with a carbapenem was suggested
for bloodstream infections caused by carbapenemase-Please cite this article in press as: Tang H-J, et al., Colistin-sparing reg
pneumoniae isolates: Combination of tigecycline or doxycycline and g
Infection (2016), http://dx.doi.org/10.1016/j.jmii.2016.03.003producing K. pneumoniae in instances where the carbape-
nem MIC of the causative isolate was  4 mg/mL.32 The
above information and our in vitro susceptibility data
associated with aminoglycoside treatment alone or with
aminoglycoside-containing regimens supported their clin-
ical application for infections due to multidrug-resistant
pathogens.
Tigecycline is a glycylcycline that exhibits inhibitory
activity in vitro against many multidrug-resistant Gram-
negative organisms, including KPC-producing K. pneumo-
niae isolates. However, current tigecycline dosages rec-
ommended for adults attain low serum concentrations for
the treatment of bloodstream infections due to so-called
“tigecycline-susceptible” isolates. Sporadic reports of
treatment failure were published with regard to tigecycline
monotherapy for the treatment of serious multidrug-
resistant infections.33 Moreover, there were increasing
numbers of tigecycline-resistant K. pneumoniae isolates.
The above concerns precluded tigecycline monotherapy,
but the efficacy of tigecycline-based combinations was not
excluded. Tigecycline in combination with polymyxin B
exhibited synergistic activity.14 Although our 12 KPC-
producing K. pneumoniae isolates were susceptible to
tigecycline, the tigecycline MIC of 10 isolates was 2 mg/mL,
and the serum-attainable concentrations of tigecycline
were 0.38 mg/mL and 0.93 mg/mL after single-dose in-
jections of 50 mg and 100 mg tigecycline, respectively,34
each < 2 mg/mL. However, if 1/2 MIC of tigecycline
(i.e., 1 mg/mL) was used in combination with gentamicin or
amikacin, synergism was present for 70e85% of the tested
isolates. Therefore, when we prescribe recommended
dosages to formulate tigecycline-based combination regi-
mens, the synergistic effect would not be evident due to
low serum levels of tigecycline (< 1 mg/mL). However,
higher levels of tigecycline can be achieved in the skin, soft
tissues, or lungs, and may overcome such setbacks.
Other agents exhibiting in vitro activity against KPC-
producing isolates included aminoglycosides, including
gentamicin and amikacin, in this study. Moreover, either
aminoglycoside in combination with doxycycline at sub-
inhibitory concentrations demonstrated synergistic activ-
ity against all 13 KPC-producing isolates, irrespective ofimens against Klebsiella pneumoniae carbapenemase-producing K.
entamicin or amikacin, Journal of Microbiology, Immunology and
Figure 1. The pulsed-field gel electrophoresis profiles of 36 Klebsiella pneumoniae carbapenemase-producing K. pneumoniae
isolates categorized into five genotypes.
Table 2 Clinical sources, pulsotypes, and MICs of four study drugs of 13 Klebsiella pneumoniae carbapenemase-producing K.
pneumoniae isolates.
Variables Isolate no.
MIC (mg/mL)
1 3 7 8 11 12 14 19 22 26 29 32 35
Source Blood Urine Urine Sputum BAL Wound Sputum Blood Urine Wound Urine Sputum Urine
PFGE type A6 A1 A5 B C5 C1 C5 C3 D1 D7 D11 D10 E
Amikacin 32 2 2 32 2 2 1 2 1 2 4 1 4
Gentamicin 32 1 1 32 1 0.5 1 0.5 0.5 1 1 0.5 1
Doxycycline 4 4 4 4 8 4 4 4 4 4 64 4 64
Tigecycline 2 1 1 2 2 2 2 2 2 2 2 2 4
BAL Z bronchial alveolar lavage; PFGE Z pulsed-field gel electrophoresis.
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Table 3 The in vitro antibacterial activity of amikacin combined with doxycycline or tigecycline against Klebsiella pneu-
moniae carbapenemase-producing K. pneumoniae isolates.
Combination regimensa Colony changes (log10 CFU/mL) at 24 h
1 3 7 8 11 12 14 19 22 26 29 32 35 Mean
1AMK þ 1DOX
vs. initial inoculum 2.65 3.83 4.20 1.17 3.81 3.78 3.86 4.08 3.49 3.51 ND 4.20 ND 3.51
vs. most active drug 4.81 1.87 2.79 2.97 4.26 1.98 6.92 4.70 5.52 5.38 ND 6.53 ND 4.34
1/2AMK þ 1/2DOX
vs. initial inoculum 2.09 3.83 4.20 1.94 3.51 3.78 2.71 2.40 3.79 3.51 ND 3.00 ND 3.16
vs. most active drug 5.30 6.82 7.00 5.30 6.67 6.86 3.00 5.16 6.89 6.76 ND 5.80 ND 5.96
1/4AMK þ 1/4DOX
vs. initial inoculum þ1.68 2.93 2.79 þ2.94 1.27 1.40 þ3.14 þ2.71 þ3.00 þ1.49 ND þ2.35 ND þ0.81
vs. most active drug 1.52 5.88 5.59 0.42 4.47 4.53 0.00 0.21 0.21 1.38 ND 0.44 ND 2.24
1AMK þ 1TGC
vs. initial inoculum 3.48 4.15 4.26 2.50 3.85 3.72 3.83 4.08 3.79 4.00 2.59 3.90 3.51 3.66
vs. most active drug 0.48 1.78 2.62 4.00 3.41 1.26 7.00 2.73 7.00 5.70 5.70 6.48 1.26 3.80
1/2AMK þ 1/2TGC
vs. initial inoculum 2.63 þ0.76 0.39 2.46 þ0.84 3.72 þ2.85 4.08 0.49 4.00 þ2.99 3.90 1.90 1.24
vs. most active drug 5.85 2.02 3.10 5.25 2.32 6.93 0.32 6.85 3.59 6.72 0.12 7.00 5.10 4.24
1/4AMK þ 1/4TGC
vs. initial inoculum þ2.94 þ2.36 þ2.44 þ2.56 þ2.80 þ3.05 þ2.77 þ2.43 þ2.81 þ3.00 þ3.11 þ2.51 þ2.89 þ2.74
vs. most active drug 0.28 0.21 0.15 0.16 0.36 0.13 0.40 0.49 0.40 0.24 0.00 0.12 0.30 0.21
a MIC-equivalent doses in combination.
AMK Z amikacin; CFU Z colony forming unit; DOX Z doxycycline; MIC Z minimum inhibitory concentration; ND Z not determined;
TGC Z tigecycline.
Table 4 The in vitro antibacterial activity of gentamicin combined with doxycycline or tigecycline against Klebsiella pneu-
moniae carbapenemase-producing K. pneumoniae isolates.
Combination regimensa Colony changes (log10 CFU/mL) at 24 h
1 3 7 8 11 12 14 19 22 26 29 32 35 Mean
1GM þ 1DOX
vs. initial inoculum 3.72 3.87 3.87 2.46 3.90 3.76 3.95 3.75 3.85 3.83 ND 4.20 ND 3.74
vs. most active drug 0.00 0.00 2.56 3.05 0.00 6.56 4.78 6.72 4.38 3.64 ND 0.00 ND 2.88
1/2GM þ 1/2DOX
vs. initial inoculum 1.24 3.87 3.87 2.24 3.90 3.76 3.95 1.97 3.85 3.83 ND 4.20 ND 3.34
vs. most active drug 4.29 6.83 6.87 4.17 6.79 6.83 5.72 4.03 6.85 5.53 ND 7.00 ND 5.90
1/4GM þ 1/4DOX
vs. initial inoculum þ2.15 2.09 2.49 þ2.86 2.90 þ2.14 þ2.79 þ3.15 þ2.23 þ0.13 ND 1.14 ND þ0.83
vs. most active drug 1.13 4.00 5.26 0.42 3.89 1.10 1.02 0.10 0.77 3.04 ND 1.66 ND 1.85
1GM þ 1TGC
vs. initial inoculum 3.73 3.75 3.73 3.72 3.76 3.76 3.85 3.82 3.78 3.82 4.38 4.08 4.15 3.87
vs. most active drug 1.20 0.00 3.82 1.81 5.20 6.62 3.73 5.73 5.89 1.08 3.70 3.76 0.00 3.27
1/2GM þ 1/2TGC
vs. initial inoculum 3.43 þ2.85 þ3.27 1.27 1.42 þ0.86 2.20 2.10 þ2.97 3.82 4.38 4.08 4.15 1.30
vs. most active drug 5.64 0.11 0.00 2.32 4.19 1.72 5.15 3.43 0.25 6.20 7.00 7.00 7.00 3.85
1/4GM þ 1/4TGC
vs. initial inoculum þ3.15 þ2.81 þ2.80 þ3.13 þ2.04 þ1.74 þ2.30 þ1.06 þ2.88 þ0.93 þ2.62 þ2.40 þ1.48 þ2.26
vs. most active drug 0.12 0.08 0.11 0.37 0.05 1.12 0.43 1.96 0.04 2.25 0.00 0.52 1.38 0.58
a MIC-equivalent doses in combination.
DOX Z doxycycline; CFU Z colony forming unit; GM Z gentamicin; MIC Z minimum inhibitory concentration; ND Z not determined;
TGC Z tigecycline.
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Table 5 Summary of in vitro antibacterial activity of amikacin or gentamicin combined with doxycycline or tigecycline against
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates.
Combination regimens Total isolate No. Isolate no. (%)
Bacteriostatic Bactericidal Synergy Antagonism
Amikacin þ Doxycycline
1MIC þ 1MIC 11 1 (9.1) 9 (81.8) 9 (81.8) 0 (0)
1/2MIC þ 1/2MIC 11 3 (27.3) 7 (63.3) 11 (100) 0 (0)
1/4MIC þ 1/4MIC 11 2 (18.2) 0 (0) 4 (36.4) 0 (0)
Amikacin þ Tigecycline
1MIC þ 1MIC 13 2 (15.4) 11 (84.6) 9 (69.2) 0 (0)
1/2MIC þ 1/2MIC 13 2 (15.4) 4 (30.8) 11 (84.6) 0 (0)
1/4MIC þ 1/4MIC 13 0 (0) 0 (0) 0 (0) 0 (0)
Gentamicin þ Doxycycline
1MIC þ 1MIC 11 1 (9.1) 10 (90.9) 7 (63.6) 0 (0)
1/2MIC þ 1/2MIC 11 1 (9.1) 8 (72.7) 11 (100) 0 (0)
1/4MIC þ 1/4MIC 11 3 (27.3) 0 (0) 4 (36.4) 0 (0)
Gentamicin þ Tigecycline
1MIC þ 1MIC 13 0 (0) 13 (100) 8 (61.5) 0 (0)
1/2MIC þ 1/2MIC 13 2 (15.4) 5 (38.5) 9 (69.2) 0 (0)
1/4MIC þ 1/4MIC 13 0 (0) 0 (0) 1 (7.7) 0 (0)
MIC Z minimal inhibitory concentration.
Table 6 Summary of checkerboard assays of amikacin or gentamicin combined with doxycycline or tigecycline against 13
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates.
Combinations Fractional inhibitory concentration index Synergy (%) Indifference (%) Antagonism (%)
Mean  SD Range 50% 90%
AMKþTGC 0.63  0.19 0.37e1 0.56 1 36.4 63.6 0.0
AMKþDOX 0.56  0.16 0.31e1 0.51 0.75 48.5 51.5 0.0
GMþTGC 0.68  0.19 0.37e1 0.62 1 28.6 71.4 0.0
GMþDOX 0.51  0.20 0.25e1 0.5 0.75 67.6 32.4 0.0
AMK Z amikacin; DOX Z doxycycline; GM Z gentamicin; SD Z standard deviation; TGC Z tigecycline.
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nation regimens at drug concentrations of 1 MIC can be
bactericidal to 80e90% of these isolates, indicative of the
potential role of these colistin-sparing combinations for
KPC producers.
Doxycycline is well established for use as a monotherapy
against Gram-negative organisms, including Klebsiella
species.35,36 However, clinical efficacy of doxycycline
therapy for infections due to multidrug-resistant Gram-
negative bacilli has not yet been defined.14 Although most
isolates are susceptible to doxycycline, it is important to
note that MIC50 values for doxycycline are near the sus-
ceptibility breakpoint (4 mg/mL). Moreover, drug concen-
trations at sites of infection should be taken into account
before their clinical use.20 However, tissue penetration of
doxycycline is excellent, and drug levels in most organs and
tissues, including kidney, lung, and sinus secretions, are
within the therapeutic range.37 The serum-attainable con-
centration of doxycycline was 3.5 mg/mL after oral
administration of 100 mg doxycycline.38 For combination
therapy using 1/2 MIC of doxycycline (2 mg/mL, which isPlease cite this article in press as: Tang H-J, et al., Colistin-sparing reg
pneumoniae isolates: Combination of tigecycline or doxycycline and g
Infection (2016), http://dx.doi.org/10.1016/j.jmii.2016.03.003achievable in serum), synergism is predominant and sug-
gestive of the potential role of doxycycline-based combi-
nations in clinical practice. Jernigan et al12 suggested that
doxycycline plus gentamicin was synergistic against 25% of
12 KPC-producing isolates, and they reserved doxycycline-
containing regimens for the treatment of uncomplicated
cystitis at their center.12 By contrast, our study found that
sub-inhibitory concentrations of an aminoglycoside com-
bined with doxycycline exhibited synergistic activity
against all tested isolates. Thus, doxycycline alone or in
combination with an aminoglycoside possesses potential
antibacterial activity and can be considered an alternative
for CRE infections.
In conclusion, enhanced antibacterial activity of doxy-
cycline plus gentamicin or amikacin was observed against
KPC-producing K. pneumoniae isolates, and warrants clin-
ical validation of their therapeutic efficacy.
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